OXFORD BIODYNAMICS PLC (LON:OBD)
SECTOR – HEALTHCARE
MARKET CAP – £207m
CURRENT PRICE – 240p#
Study data presented at diabetes conference
NORTHLAND VIEW
Oxford BioDynamics presented study data regarding its proprietary Episwitch™ platform at the Diabetes Asia 2017 Conference in Malaysia.
Type II diabetes mellitus (TD2) is a growing health issue in Asia. Between 2016 and 2011, prevalence of T2D in Malaysia increased by 31%.
Prior to developing T2D, patients progress through a ‘pre-diabetes’ stage. Studies have shown that clinical intervention at the pre-diabetes stage can halt progression to full T2D.
In this study, 270 patients were categorised into four groups dependent on their TD2 status (healthy, prediabetes stage, treatment-naive and diabetes with treatment).
The study showed that after six months only 4% of patients with diabetes regressed to the healthy group whilst 44% of participants in the pre-diabetes stage regressed to the healthy group. Using epigenetic biomarkers, the Company’s Episwitch™ platform could identify individuals in the prediabetes stage, the period where TD2 can be prevented.
Dr Alexandre Akoulitchev, Chief Scientific Officer of Oxford BioDynamics, commented: "This study demonstrates that there is considerable clinical utility in using our EpiSwitch™ technology to identify those at the pre-diabetic phase, and could be a powerful tool in tackling the overall increasing prevalence of diabetes.”
COMPANY DESCRIPTION
Oxford BioDynamics is a clinical stage biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture for use within the pharmaceutical and biotechnology industry.